L

Lite Strategy Inc.
D

LITS

1.93000
USD
0.10
(5.18%)
مغلق
حجم التداول
0
الربح لكل سهم
-9
العائد الربحي
-
P/E
-1
حجم السوق
70,995,816
المقالات

العنوان: Lite Strategy Inc.

القطاع: Healthcare
الصناعة: Biotechnology
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily,selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.